Cellectis S.A. American Depositary Shares (CLLS)
Stock · NASDAQ · Health Care
$1.04as of 10/16/2026
Price chart
Active signals
CLLS Signal Track Record
How signals performed across all stocks →What CLLS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +0.4% | 51% | September 10, 2026 |
| Bollinger Band Breakout | 24 | -4.5% | 29% | August 12, 2026 |
| Bollinger Band Breakdown | 22 | +2.4% | 59% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +10.3% | 60% | May 4, 2026 |
| Any 20-session window (baseline) | -3.3% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients wi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 224
- Website
- www.cellectis.com/
Fundamentals
- 1-day range
- $1.03$1.12
- Market cap
- $270.42M
- P/E (trailing)
- —
- P/E (forward)
- -1.68
- EPS (trailing)
- $-0.82
- Dividend yield
- —
- Beta
- 1.22
- Avg. volume
- 86.7K
Forecasts
4 analyst ratings
Cellectis S.A. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- European Equities Traded in US as ADRs Fall in Thursday TradingYahoo · 10/8/2026
- European Equities Traded in US as ADRs Fall in Wednesday TradingYahoo · 10/7/2026
- Monthly information on share capital and company voting rightsYahoo · 10/6/2026
- European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday TradingYahoo · 10/6/2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Monday TradingYahoo · 10/5/2026
- European Equities Traded in the US as American Depositary Receipts Track Higher in Friday TradingYahoo · 10/2/2026
- Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid DisordersYahoo · 10/1/2026
- European Equities Traded in the US as American Depositary Receipts Decline in Wednesday TradingYahoo · 9/30/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 10.25M
- Total value held
- $32.49M
- Institutional holders
- 31
- Unknown3.28M
- Unknown3.18M
- Unknown2.74M
- Unknown341.5K
- Unknown226.9K
- Unknown86.8K
- Unknown84.3K
- Unknown65.9K
- Unknown44.3K
- Unknown41.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Cellectis ADRs Follow Broader European Equity Trends
Cellectis shares have moved in line with general European equity trading patterns over the past week, seeing declines on Tuesday through Thursday after a rise on Monday. The stock is currently trading near its 52-week low, which provides context for the recent price action amidst broader market fluctuations. No company-specific news was reported during this period.
Cellectis ADRs Follow Broader European Equity Trends. Cellectis shares have moved in line with general European equity trading patterns over the past week, seeing declines on Tuesday through Thursday after a rise on Monday. The stock is currently trading near its 52-week low, which provides context for the recent price action amidst broader market fluctuations. No company-specific news was reported during this period.